| Description | LY117018 shows antiproliferative effects on breast cancer cell lines. LY117018 is a Raloxifene analog and is a selective estrogen receptor modulator. |
| In vitro | LY117018 (1 μM) treatment, caused a predominantly hypophosphorylated pRb. At a higher concentration of LY117018 (1 μM), the level of p53 appeared to decline. LY117018 (0.01-1000 nM; 24 hours) at lower concentrations (0.01-10 nM) caused an E2-like increase in p53 levels when compared to its effects on cells grown in the stripped medium. LY117018 did not block E2-induced pRb phosphorylation, at lower concentrations[1]. LY117018 (1 μM; 96 hours) suppresses MCF-7 cell proliferation with an IC50 of 1 μM[2]. LY117018 inhibits oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway[3]. |
| molecular weight | 459.56 |
| Molecular formula | C27H25NO4S |
| CAS | 63676-25-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Dinda S, et al. Effects of LY117018 (a SERM analog of raloxifene) on tumor suppressor proteins and proliferation of breast cancer cells.Horm Mol Biol Clin Investig. 2010 Aug 1;2(1):211-7. 2. Baumann KH, et al. Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Breast Cancer (Auckl). 2009 Apr 7;3:23-34. 3. Yu J, et al.Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway.Eur J Pharmacol. 2008 Jul 28;589(1-3):32-6. |